Buhai Wang

6.5k total citations
41 papers, 630 citations indexed

About

Buhai Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Buhai Wang has authored 41 papers receiving a total of 630 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Buhai Wang's work include Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (9 papers) and Esophageal Cancer Research and Treatment (6 papers). Buhai Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Treatments and Mutations (9 papers) and Esophageal Cancer Research and Treatment (6 papers). Buhai Wang collaborates with scholars based in China, United States and United Kingdom. Buhai Wang's co-authors include Yan Shen, Ammar Ouahab, Xizhi Zhang, Xingxiang Xu, Wei Liu, Longbang Chen, Jiasheng Tu, Yong Chen, Liqin Liu and Ying Sun and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Controlled Release.

In The Last Decade

Buhai Wang

41 papers receiving 623 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Buhai Wang China 13 269 245 239 185 80 41 630
Shude Cui China 14 290 1.1× 139 0.6× 233 1.0× 276 1.5× 48 0.6× 42 610
Sergio Vázquez‐Estévez Spain 15 233 0.9× 212 0.9× 192 0.8× 97 0.5× 158 2.0× 76 585
Zhongzhen Guan China 8 233 0.9× 133 0.5× 142 0.6× 93 0.5× 73 0.9× 26 600
Karel Cwiertka Czechia 10 247 0.9× 123 0.5× 115 0.5× 108 0.6× 48 0.6× 45 436
Xuelian Chen China 12 462 1.7× 209 0.9× 218 0.9× 163 0.9× 149 1.9× 36 779
Minsig Choi United States 14 360 1.3× 134 0.5× 190 0.8× 104 0.6× 82 1.0× 28 549
Lara Buchmiller United States 7 361 1.3× 281 1.1× 181 0.8× 94 0.5× 81 1.0× 7 600
Yuejuan Xu China 13 153 0.6× 152 0.6× 189 0.8× 181 1.0× 73 0.9× 20 499
Michael A. Dengler Germany 14 109 0.4× 118 0.5× 455 1.9× 143 0.8× 109 1.4× 24 706
Alessandra Bulotta Italy 14 406 1.5× 249 1.0× 264 1.1× 124 0.7× 23 0.3× 47 695

Countries citing papers authored by Buhai Wang

Since Specialization
Citations

This map shows the geographic impact of Buhai Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Buhai Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Buhai Wang more than expected).

Fields of papers citing papers by Buhai Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Buhai Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Buhai Wang. The network helps show where Buhai Wang may publish in the future.

Co-authorship network of co-authors of Buhai Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Buhai Wang. A scholar is included among the top collaborators of Buhai Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Buhai Wang. Buhai Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Jinsong, Cui Liu, Fengjun Cao, et al.. (2025). Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial. Radiotherapy and Oncology. 206. 110797–110797. 1 indexed citations
2.
Wang, Buhai, et al.. (2024). Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer. Journal for ImmunoTherapy of Cancer. 12(11). e009898–e009898. 2 indexed citations
3.
Ye, Zixuan, Yanyan Liu, Yan Zhao, et al.. (2024). Hybrid nanopotentiators with dual cascade amplification for glioma combined interventional therapy. Journal of Controlled Release. 372. 95–112. 9 indexed citations
4.
Zhou, Qing, Lin Wu, Bo Jiang, et al.. (2023). Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.. Journal of Clinical Oncology. 41(16_suppl). 2570–2570. 4 indexed citations
5.
Meng, Xue, Jun Wang, Xiao‐Yuan Wu, et al.. (2023). Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial. British Journal of Cancer. 129(11). 1787–1792. 12 indexed citations
6.
Yang, Jianqi, et al.. (2023). Construction of Prognostic Nomogram in Patients with N3-Stage Nasopharyngeal Carcinoma. ORL. 85(4). 195–207. 2 indexed citations
7.
8.
Wang, Jie, Yi‐Long Wu, Shun Lü, et al.. (2023). Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis. JTO Clinical and Research Reports. 5(2). 100621–100621. 4 indexed citations
9.
Wang, Buhai, et al.. (2022). Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study. Technology in Cancer Research & Treatment. 21. 2213880101–2213880101. 2 indexed citations
10.
11.
Cheng, Ying, Yong He, Wěi Li, et al.. (2021). Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Targeted Oncology. 16(2). 165–176. 90 indexed citations
12.
Xu, Jianming, Yuxian Bai, Nong Xu, et al.. (2020). Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 26(17). 4542–4550. 70 indexed citations
13.
Zhao, Dan, et al.. (2020). Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients. Frontiers in Oncology. 10. 691–691. 17 indexed citations
14.
Zhang, Xizhi, et al.. (2016). Association Between Polymorphism rs678653 in Human Cyclin D1 Gene (CCND1) and Susceptibility to Cancer: A Meta-Analysis. Medical Science Monitor. 22. 863–874. 3 indexed citations
15.
Ye, Jing, et al.. (2016). Differentiation between recurrent gliomas and radiation necrosis using arterial spin labeling perfusion imaging. Experimental and Therapeutic Medicine. 11(6). 2432–2436. 37 indexed citations
16.
Wang, Buhai, Wei Hua, Xiang Gu, et al.. (2015). Dosimetric study of different radiotherapy planning approaches for hippocampal avoidance whole-brain radiation therapy (HA-WBRT) based on fused CT and MRI imaging. Australasian Physical & Engineering Sciences in Medicine. 38(4). 767–775. 13 indexed citations
17.
Chen, Yong, Xizhi Zhang, Buhai Wang, et al.. (2013). Decreased miRNA-148a is associated with lymph node metastasis and poor clinical outcomes and functions as a suppressor of tumor metastasis in non-small cell lung cancer. Oncology Reports. 30(4). 1832–1840. 35 indexed citations
18.
Chen, Yong, Ying Sun, Longbang Chen, et al.. (2013). miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Molecular Medicine Reports. 7(5). 1579–1584. 75 indexed citations
19.
Wang, Buhai, et al.. (2012). Gemcitabine-based Concurrent Chemoradiotherapy Versus Chemotherapy Alone in Patients with Locally Advanced Pancreatic Cancer. Asian Pacific Journal of Cancer Prevention. 13(5). 2129–2132. 8 indexed citations
20.
Shen, Yan, Buhai Wang, Yang Lu, et al.. (2011). A novel tumor-targeted delivery system with hydrophobized hyaluronic acid–spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery. International Journal of Pharmaceutics. 414(1-2). 233–243. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shude Cui Breakdown of academic impact, for papers by Sergio Vázquez‐Estévez Breakdown of academic impact, for papers by Zhongzhen Guan Breakdown of academic impact, for papers by Karel Cwiertka Breakdown of academic impact, for papers by Xuelian Chen Breakdown of academic impact, for papers by Minsig Choi Breakdown of academic impact, for papers by Lara Buchmiller Breakdown of academic impact, for papers by Yuejuan Xu Breakdown of academic impact, for papers by Michael A. Dengler Breakdown of academic impact, for papers by Alessandra Bulotta
Rankless by CCL
2026